At a glance
ClinicalIndex Comparison RecordPhase 3Active· 605 enrolled
Drug / intervention
DS-1062a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01)
In Brief
A Phase 3 clinical trial evaluating DS-1062a and Docetaxel for Non-small Cell Lung Cancer. Active but no longer recruiting, targeting 605 participants across 209 sites in 26 countries.
Detailed Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesArgentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Hong Kong, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, Singapore, South Korea, Spain, Switzerland, Taiwan, United Kingdom, United States
CollaboratorsAstraZeneca
Timeline
Phase 3Active
2021202220232024202520262027
First PostedDec 2020
Enrollment StartDec 2020
Primary CompletionMay 2024
TodayJul 2026
Study CompletionFeb 2027
First PostedDec 7, 2020
Enrollment StartDec 21, 2020
Primary CompletionMay 10, 2024
Study CompletionFeb 15, 2027
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 5.6 years ago
Interventions
DS-1062adrug
DS-1062a will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
Docetaxeldrug
Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.